<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00813527</url>
  </required_header>
  <id_info>
    <org_study_id>01-05-TL-475-031</org_study_id>
    <secondary_id>U1111-1122-8178</secondary_id>
    <nct_id>NCT00813527</nct_id>
  </id_info>
  <brief_title>Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels</brief_title>
  <official_title>A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 or Placebo When Coadministered With Fenofibrate in Subjects With Combined Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare changes in cholesterol levels in patients with
      elevated blood cholesterol with administration of lapaquistat acetate, once daily (QD), and
      fenofibrate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elevated plasma cholesterol (hypercholesterolemia) and various other plasma lipid imbalances
      (dyslipidemias) are major risk factors for coronary heart disease. It has been established
      that lowering the low-density lipoprotein cholesterol plasma concentration effectively
      reduces cardiovascular morbidity and mortality. As a result of this finding, the National
      Cholesterol Education Program Adult Treatment Panel III identifies control of low-density
      lipoprotein cholesterol as essential in the prevention and management of coronary heart
      disease.

      Currently, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are the
      first-line monotherapies prescribed to reduce low-density lipoprotein cholesterol, after diet
      and therapeutic lifestyle change. However, low doses of statins often fail to produce the
      Adult Treatment Panel III-recommended levels of low-density lipoprotein cholesterol
      reduction, making it necessary to increase the dose or add an additional treatment. This in
      turn may result in decreased tolerability and potential safety concerns.

      At higher doses, statins are associated with various myopathies ranging from rare occurrences
      of rhabdomyolysis and myositis to more frequent symptoms of muscle weakness, cramps, or pain;
      these can occur with mild or no increases in creatine kinase. Statin use also is associated
      with increases in liver transaminase levels. These tolerability and safety concerns may
      contribute to the high discontinuation rates of statins and their prescription at low, and
      often ineffective, doses.

      TAK-475 (lapaquistat acetate) inhibits the cholesterol synthesis pathway at a different step
      than statins (acting on squalene synthase rather than 3-hydroxy-3-methylglutaryl coenzyme A);
      it does not reduce concentrations of isoprenylated intermediates believed to be responsible
      for the myopathies associated with statin use.

      This study was conducted to determine whether lapaquistat acetate with fenofibrate has the
      potential to be more effective than fenofibrate by itself in lowering low-density lipoprotein
      cholesterol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from Baseline in direct fasting plasma low-density lipoprotein cholesterol.</measure>
    <time_frame>Week 12 or Final Visit.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in calculated low-density lipoprotein cholesterol.</measure>
    <time_frame>Week 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in non- high-density lipoprotein cholesterol.</measure>
    <time_frame>Week 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total cholesterol.</measure>
    <time_frame>Week 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in apolipoprotein B.</measure>
    <time_frame>Week 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in triglycerides.</measure>
    <time_frame>Week 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in high-density lipoprotein cholesterol.</measure>
    <time_frame>Week 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in apolipoprotein A1.</measure>
    <time_frame>Week 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in very-low-density lipoprotein cholesterol.</measure>
    <time_frame>Week 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in derived ratios including total cholesterol/high-density lipoprotein cholesterol, low-density lipoprotein cholesterol/high-density lipoprotein cholesterol, and apolipoprotein B/ apolipoprotein Al.</measure>
    <time_frame>Week 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in high-sensitivity C-reactive protein.</measure>
    <time_frame>Week 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving Target Direct low-density lipoprotein cholesterol Levels.</measure>
    <time_frame>Week 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">213</enrollment>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>Lapaquistat Acetate 100 mg QD + Fenofibrate 145 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fenofibrate 145 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapaquistat acetate and fenofibrate</intervention_name>
    <description>Lapaquistat acetate 100 mg, tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.</description>
    <arm_group_label>Lapaquistat Acetate 100 mg QD + Fenofibrate 145 mg QD</arm_group_label>
    <other_name>Lapaquistat</other_name>
    <other_name>TAK-475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>Lapaquistat acetate placebo-matching tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.</description>
    <arm_group_label>Fenofibrate 145 mg QD</arm_group_label>
    <other_name>Tricor</other_name>
    <other_name>Trilipix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women of childbearing potential must not be pregnant as determined by a negative serum
             human chorionic gonadotropin, not lactating, not planning on becoming pregnant between
             Screening and 30 days following the last dose of study medication, and agreed to use
             acceptable forms of contraception during the study.

          -  Prior to Randomization, must have a mean low density lipoprotein cholesterol greater
             than or equal to 100 mg/dL (2.59 mmol/L) for 2 consecutive samples. The difference
             between the two individual low density lipoprotein cholesterol values not to exceed
             15% of the higher value.

          -  Prior to Randomization, must have mean triglycerides greater than or equal to 150 and
             less than or equal to 600 mg/dL (1.70 and 6.78 mmol/L, respectively) for 2 consecutive
             samples. The upper value for either triglycerides sample must have been less than or
             equal to 650 mg/dL (7.35 mmol/L).

          -  Clinical laboratory evaluations (including clinical chemistry [fasted for at least 10
             hours], hematology and urinalysis) within the reference range for the testing
             laboratory unless results deemed not clinically significant or considered within
             normal limits for this subject by the investigator or the sponsor.

          -  Willing and able to continue to comply with a standardized low cholesterol diet.

        Exclusion Criteria:

          -  Alanine aminotransferase or aspartate aminotransferase level of greater than 1.5 times
             the upper limit of normal, active liver disease or jaundice.

          -  Serum creatinine greater than 1.5 mg/dL (133 Î¼mol/L).

          -  Creatine phosphokinase greater than 3 times the upper limit of normal.

          -  Diabetes with a hemoglobin A1c greater than 8 % at Visit 1.

          -  Previous history of cancer in remission for less than 5 years prior to the first dose
             of study medication. Does not include those subjects with basal cell or stage I
             squamous cell carcinoma of the skin.

          -  An endocrine disorder, such as Cushing's syndrome, hyperthyroidism, or inappropriately
             treated hypothyroidism, affecting lipid metabolism. Subjects with hypothyroidism on
             appropriate replacement therapy (defined as stable thyroid hormone replacement therapy
             at least 3 months prior to Visit 1 and thyrotropin levels less than 1.5 times the
             upper limit of normal) are eligible for enrollment. If thyrotropin is greater than 1.5
             times upper limit of normal, a free thyroxine level is to be determined. If the free
             thyroxine is within normal limits for that subject, the subject may continue in the
             study.

          -  History of myocardial infarction, unstable angina, transient ischemic attacks,
             cerebrovascular accident, percutaneous coronary intervention, coronary or peripheral
             arterial surgery (bypass graft surgery) in the 6 months prior to Visit 1.

          -  Positive hepatitis B surface antigen, or hepatitis C virus antibody, as determined by
             medical history and/or subject's verbal report.

          -  Positive human immunodeficiency virus status or is taking anti-retroviral medications,
             as determined by medical history and/or subject's verbal report.

          -  Unable or unwilling to discontinue excluded medications or to continue stable doses of
             &quot;stable dose&quot; medications or required treatment with any excluded medication during
             the study.

          -  Exposure to TAK-475 in other studies or currently is participating in another
             investigational study or has participated in an investigational study within the past
             30 days or, for drugs with a long half-life, within a period of less than 5 times the
             drug's halflife.

          -  Known hypersensitivity or history of adverse reaction to any fibrate.

          -  History or presence of clinically significant food allergy that would prevent
             adherence to the therapeutic lifestyle change (or equivalent) diet.

          -  Known homozygous familial hypercholesterolemia or known Type III hyperlipoproteinemia
             (familial dysbetalipoproteinemia).

          -  Active cholecystitis or known cholelithiasis (a fibrate risk factor).

          -  Severe renal or hepatic dysfunction, including biliary cirrhosis during Run-In or at
             Randomization (a fibrate risk factor).

          -  Fibromyalgia, myopathy, rhabdomyolysis or unexplained muscle pain.

          -  Uncontrolled hypertension (defined as resting diastolic blood pressure greater than100
             mm Hg or resting systolic blood pressure greater than 160 mm Hg) at Visit 1.

          -  Inflammatory bowel disease or any other malabsorption syndrome or has had gastric
             bypass or any other surgical procedure for weight loss.

          -  Unwilling or unable, in the opinion of the investigator, to comply with the protocol
             or scheduled appointments.

          -  Unable to understand verbal or written English or any other language for which a
             certified translation of the approved informed consent was available.

          -  History of drug abuse (defined as illicit drug use) or a history of alcohol abuse
             (defined as regular or daily consumption of more than 2 alcoholic drinks per day)
             within the past 2 years.

          -  Any other serious disease or condition at Screening or at Randomization that might
             reduce life expectancy, impair successful management according to the protocol, or
             make the subject an unsuitable candidate to receive study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sierra Vista</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warner Robins</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hillsboro</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goose Creek</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Stein EA, Bays H, O'Brien D, Pedicano J, Piper E, Spezzi A. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation. 2011 May 10;123(18):1974-85. doi: 10.1161/CIRCULATIONAHA.110.975284. Epub 2011 Apr 25.</citation>
    <PMID>21518985</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2008</study_first_submitted>
  <study_first_submitted_qc>December 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2008</study_first_posted>
  <last_update_submitted>May 23, 2012</last_update_submitted>
  <last_update_submitted_qc>May 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <keyword>Lipid Metabolism Disorders</keyword>
  <keyword>Hyperlipidemias</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Hypertriglyceridemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

